Zi Ye1, Chunyan Wu2,3,4, Ni Zhang1, Liping Du1, Qingfeng Cao1, Xinyue Huang1, Jihong Tang1, Qingfeng Wang1, Fuzhen Li5, Chunjiang Zhou1, Qian Xu4, Xiao Xiong4, Aize Kijlstra6, Nan Qin2,3,4, Peizeng Yang1. 1. The First Affiliated Hospital of Chongqing Medical University , Chongqing Key Lab of Ophthalmology, Chongqing Eye Institute, Chongqing, China. 2. Department of General Surgery, Shanghai Tenth People's Hospital, Tongji University School of Medicine , Shanghai, China. 3. Institute of Intestinal Diseases, Tongji University School of Medicine , Shanghai, China. 4. Institute of Intestinal Diseases, Realbio Genomics Institute , Shanghai, China. 5. Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, China. 6. University Eye Clinic Maastricht , Maastricht, The Netherlands.
Abstract
BACKGROUND: Vogt-Koyanagi-Harada (VKH) disease is a multisystemic autoimmune disorder characterized by granulomatous panuveitis. Gut microbiome has been considered to play a role in the pathogenesis of this disease but whether the alternation of gut microbiome was involved is unclear. This study was set up to identify abnormalities of gut microbiome composition in VKH disease. RESULTS: Depleted butyrate-producing bacteria, lactate-producing bacteria and methanogens as well as enriched Gram-negative bacteria were identified in the active VKH patients, as well as in VKH patients of Mix enterotype and Bacteroides enterotype. Changes of gut microbiome in the VKH patients were partially restored after an immunosuppressive treatment. The disease susceptibility genotype HLA-DRA was associated with Bacteroides sp.2.1.33B, Paraprevotella clara, Alistipes finegoldii and Eubacterium eligens. A microbial marker profile including 40 disease-associated species was established to differentiate patients from controls. Another microbial marker profile including 37 species was found to be associated with the response to treatment. An animal experiment showed that transfer of gut microbiome from VKH patients could significantly exacerbate disease activity clinically and pathologically in the recipient mice. CONCLUSION: Our results revealed a distinct gut microbiome signature in VKH patients and showed an exacerbating effect of this gut microbiome on experimental autoimmune uveitis (EAU). We also developed two microbial marker profiles in differentiating VKH patients from healthy controls as well as predicting the effectiveness of treatment.
BACKGROUND: Vogt-Koyanagi-Harada (VKH) disease is a multisystemic autoimmune disorder characterized by granulomatous panuveitis. Gut microbiome has been considered to play a role in the pathogenesis of this disease but whether the alternation of gut microbiome was involved is unclear. This study was set up to identify abnormalities of gut microbiome composition in VKH disease. RESULTS: Depleted butyrate-producing bacteria, lactate-producing bacteria and methanogens as well as enriched Gram-negative bacteria were identified in the active VKH patients, as well as in VKH patients of Mix enterotype and Bacteroides enterotype. Changes of gut microbiome in the VKH patients were partially restored after an immunosuppressive treatment. The disease susceptibility genotype HLA-DRA was associated with Bacteroides sp.2.1.33B, Paraprevotella clara, Alistipes finegoldii and Eubacterium eligens. A microbial marker profile including 40 disease-associated species was established to differentiate patients from controls. Another microbial marker profile including 37 species was found to be associated with the response to treatment. An animal experiment showed that transfer of gut microbiome from VKH patients could significantly exacerbate disease activity clinically and pathologically in the recipient mice. CONCLUSION: Our results revealed a distinct gut microbiome signature in VKH patients and showed an exacerbating effect of this gut microbiome on experimental autoimmune uveitis (EAU). We also developed two microbial marker profiles in differentiating VKH patients from healthy controls as well as predicting the effectiveness of treatment.
Authors: Mélanie Deschasaux; Kristien E Bouter; Andrei Prodan; Evgeni Levin; Albert K Groen; Hilde Herrema; Valentina Tremaroli; Guido J Bakker; Ilias Attaye; Sara-Joan Pinto-Sietsma; Daniel H van Raalte; Marieke B Snijder; Mary Nicolaou; Ron Peters; Aeilko H Zwinderman; Fredrik Bäckhed; Max Nieuwdorp Journal: Nat Med Date: 2018-08-27 Impact factor: 53.440
Authors: Annelies Geirnaert; Marta Calatayud; Charlotte Grootaert; Debby Laukens; Sarah Devriese; Guy Smagghe; Martine De Vos; Nico Boon; Tom Van de Wiele Journal: Sci Rep Date: 2017-09-13 Impact factor: 4.379
Authors: Jose U Scher; Andrew Sczesnak; Randy S Longman; Nicola Segata; Carles Ubeda; Craig Bielski; Tim Rostron; Vincenzo Cerundolo; Eric G Pamer; Steven B Abramson; Curtis Huttenhower; Dan R Littman Journal: Elife Date: 2013-11-05 Impact factor: 8.140
Authors: Carmen Antía Rodríguez-Fernández; Manuel Busto Iglesias; Begoña de Domingo; Kelly Conde-Pérez; Juan A Vallejo; Lorena Rodríguez-Martínez; Miguel González-Barcia; Victor Llorenç; Cristina Mondelo-Garcia; Margarita Poza; Anxo Fernández-Ferreiro Journal: Int J Mol Sci Date: 2022-06-24 Impact factor: 6.208